CRN, AHPA say FDA should consider combo products
This article was originally published in The Tan Sheet
FDA should allow supplement and drug combination products in the marketplace, executives from the Council for Responsible Nutrition and the American Herbal Products Association say at a Jan. 30 Food, Drug and Law Institute conference in Washington. "It's to FDA's advantage to help the industry" market combination products because they will benefit the public health, CRN President Steve Mister notes. Mister says FDA should advise all manufacturers on how to comply so they have "equal footing" in the marketplace. AHPA President Michael McGuffin says, "Don't tell us what we can't do. Tell us how we can do it, in a reasonable and responsible manner." FDA in October 2008 warned Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs (1"The Tan Sheet" Nov. 3, 2008, p. 9)
You may also be interested in...
Revised labeling for Heart Health Advantage, with phytosterols, suggests the product “can be added to an aspirin regimen” after a similarly branded aspirin/phytosterol combo was pulled from the market in April because FDA called it an unapproved new drug.
FDA warns Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.